DDInter1548 DDInter1676
Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue. Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia gravis since the 1930s with the early use of [physostigmine] and [neostigmine]. By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.[A231004, L32408, L32413] Pyridostigmine is the current drug of choice, with superior pharmacokinetics and reduced side effects compared to [neostigmine].[L32408, L32413] In addition to treating myasthenia gravis, pyridostigmine is used to reverse neuromuscular blocks
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Pyridostigmine {u} (Compound) resembles {v} (Compound) Neostigmine
Pyridostigmine {u} (Compound) binds {v} (Gene) BCHE
Pyridostigmine {u} (Compound) upregulates {v} (Gene) INPP4B
Pyridostigmine {u} (Compound) causes {v} (Side Effect) Cholinergic syndrome
Pyridostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fingolimod
Pyridostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Pyridostigmine (Compound) resembles Neostigmine (Compound)
Pyridostigmine (Compound) binds BCHE (Gene)
Pyridostigmine (Compound) upregulates INPP4B (Gene)
Pyridostigmine (Compound) causes Cholinergic syndrome (Side Effect)
Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone